Corrigendum to "DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer" [Canc. Lett. 501 224-233]
Cancer Lett. 2023 Jun 1:563:216196.
doi: 10.1016/j.canlet.2023.216196.
Epub 2023 Apr 25.
1 Translational Oncology Laboratory, Hematology Institute and Blood Bank, Meir Medical Center, Kfar-Saba, Israel; Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
2 Department of Pathology, Meir Medical Center, Kfar Saba, Israel; Sackler Faculty of Medicine, Israel.
3 Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Pathology, Meir Medical Center, Kfar Saba, Israel; Sackler Faculty of Medicine, Israel.
4 Clinical Research Institute at Rambam, Division of Oncology, Rambam Health Care Campus, Technion-Israel Institute of Technology, Haifa, Israel.
5 Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Gynecological Oncology Unit, The Department of Obstetrics and Gynecology, Meir Medical Center, Kfar Saba, Israel.
6 Gynecological Oncology Unit, The Department of Obstetrics and Gynecology, Meir Medical Center, Kfar Saba, Israel.
7 Biological Psychiatry Laboratory Hadassah - Hebrew University Medical Center, Jerusalem, Israel.
8 Translational Oncology Laboratory, Hematology Institute and Blood Bank, Meir Medical Center, Kfar-Saba, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
9 Translational Oncology Laboratory, Hematology Institute and Blood Bank, Meir Medical Center, Kfar-Saba, Israel; Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: osnataf@gmail.com.